Robert Dudley's most recent trade in Freeport-McMoRan Inc was a trade of 4,900 Common Stock done . Disclosure was reported to the exchange on June 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Freeport-McMoRan | Robert W. Dudley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2025 | 4,900 | 22,400 (0%) | 0% | 0 | Common Stock | |
| LyondellBasell | Robert W. Dudley | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 56.13 per share. | 23 May 2025 | 483 | 8,207 (0%) | 0% | 56.1 | 27,111 | Class A Ordinary Shares |
| LyondellBasell | Robert W. Dudley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 2,917 | 8,690 (0%) | 0% | 0 | Class A Ordinary Shares | |
| Dominari Holdings Inc | Robert Dudley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 10,000 | 22,411 (0%) | 0% | - | Common Stock | |
| Freeport-McMoRan | Robert W. Dudley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2024 | 3,500 | 17,500 (0%) | 0% | 0 | Common Stock | |
| LyondellBasell | Robert W. Dudley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 1,692 | 5,773 (0%) | 0% | 0 | Class A Ordinary Shares | |
| LyondellBasell | Robert W. Dudley | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.91 per share. | 18 May 2024 | 429 | 4,081 (0%) | 0% | 100.9 | 43,290 | Class A Ordinary Shares |
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.65 per share. | 20 Jun 2023 | 12,000 | 82,262 | - | 2.7 | 31,818 | Common Stock |
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.55 per share. | 20 Jun 2023 | 6,607 | 70,262 | - | 2.5 | 16,847 | Common Stock |
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.76 per share. | 09 Jun 2023 | 19,000 | 912,114 | - | 2.8 | 52,440 | Common Stock |
| Freeport-McMoRan | Robert W. Dudley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 5,000 | 14,000 (0%) | 0% | 0 | Common Stock | |
| LyondellBasell | Robert W. Dudley | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.31 per share. | 26 May 2023 | 281 | 4,510 (0%) | 0% | 87.3 | 24,534 | Class A Ordinary Shares |
| LyondellBasell | Robert W. Dudley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 1,860 | 4,791 (0%) | 0% | 0 | Class A Ordinary Shares | |
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2022 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.15 per share. | 14 Sep 2022 | 20,000 | 893,114 | - | 1.2 | 23,000 | Common Stock |
| Dominari Holdings Inc | Robert Dudley | Director | Grant, award, or other acquisition of securities at price $ 6.00 per share. | 26 Aug 2022 | 8,000 | 12,411 (0%) | 0% | 6 | 48,000 | Common Stock |
| Freeport-McMoRan | Robert W. Dudley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 4,500 | 9,000 (0%) | 0% | 0 | Common Stock | |
| LyondellBasell | Robert W. Dudley | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.08 per share. | 28 May 2022 | 164 | 2,931 (0%) | 0% | 117.1 | 19,201 | Class A Ordinary Shares |
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.84 per share. | 27 May 2022 | 28,000 | 871,114 | - | 1.8 | 51,643 | Common Stock |
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.87 per share. | 27 May 2022 | 2,000 | 873,114 | - | 1.9 | 3,740 | Common Stock |
| LyondellBasell | Robert W. Dudley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 1,568 | 3,095 (0%) | 0% | 0 | Class A Ordinary Shares | |
| TransCode Therapeutics Inc | Robert Michael Dudley | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
| Freeport-McMoRan | Robert W. Dudley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 3,800 | 4,500 (0%) | 0% | 0 | Common Stock | |
| LyondellBasell | Robert W. Dudley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 1,527 | 1,527 (0%) | 0% | 0 | Class A Ordinary Shares | |
| Freeport-McMoRan | Robert W. Dudley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2021 | 700 | 700 (0%) | 0% | 0 | Common Stock |